Abstract: A pod performance test system for a near space aerostat includes: a HCI test control device, a motion simulation control device, a suspension device, and a motion simulation anti-twisting mechanism. The HCI test control device is electronically connected to the motion simulation control device, the motion simulation anti-twisting mechanism and a pod of the near space aerostat separately. The motion simulation control device is electronically connected to the motion simulation anti-twisting mechanism. The motion simulation anti-twisting mechanism is connected to the pod by a connector. The motion simulation control device controls the motion simulation anti-twisting mechanism to simulate various complex motion states according to a motion control parameter from the HCI test control device, and thus the pod is in the various complex motion states. When the pod is in the various complex motion states, performance test results of the pod under the various complex motion states can be obtained.

Abstract: The disclosure is related to a meloxicam compositions, pharmaceutical preparations, preparation methods and use thereof. In one aspect of the invention, meloxicam compositions contain meloxicam and cosolvents. The cosolvents are mixed solvents including water and organic solvents. In another aspect of the invention, other compositions contain meloxicam, solvents, and pH regulators. The pH regulators include at least citric acid. The pharmaceutical compositions significantly enhance the solubility of meloxicam in liquid pharmaceutical preparations as well as stability. The meloxicam compositions can be directly used for intravenous injection administration to quickly reach effective therapeutic concentrations for post-operative analgesia.

Abstract: A vehicle-road cooperation precise positioning method based on an electrified highway includes measuring position information of its own positioning point by using a roadside positioning module; determining absolute coordinates of all points on a communication line according to the position information; acquiring a contact signal when a vehicle-road connection information system comes into contact with the communication line, and determining position information of a contact point according to the contact signal and the absolute coordinates; and based on a conversion algorithm, determining current vehicle mass center position coordinate information according to the position information of the contact point and parameter information of the vehicle-road connection information system.

Abstract: Provided are a molecular sieve catalyst, a preparation method therefor, an application thereof. The molecular sieve catalyst contains a modified Na-MOR molecular sieve, and the modification comprises: organic ammonium salt exchange, dealumination treatment, and ammonium ion exchange. The catalyst obtained by the method is used in dimethyl ether for one-step production of methyl acetate. The catalyst has high activity and stable performance, and the needs of industrial production can be satisfied.

Abstract: Provided are a pharmaceutical composition of (S)-ketorolac and a preparation method therefor, which belong to the technical field of pharmaceutical preparations. The pharmaceutical composition includes (S)-ketorolac or a pharmaceutically acceptable salt thereof, a stabilizer, a pH-adjusting agent, and an excipient, and the dosage form of the pharmaceutical composition is preferably lyophilized powder injection. The lyophilized powder injection prepared herein has optical purity of an active ingredient greater than or equal to 95% after being stored under long-term stability test conditions for 6 months and optical purity of an active ingredient greater than or equal to 90% after being stored under accelerated stability test conditions for 6 months. The lyophilized powder injection has important use in the preparation of non-steroidal anti-inflammatory drugs with analgesic, anti-inflammatory, antipyretic effects.

Abstract: A ketorolaco derivative as shown in formula (I) has a better half-life and stability, has good pharmacokinetic properties, and has a higher stability in vitro; and as a preparation, the ketorolaco derivative can enhance efficacy and reduce toxicity. The present invention well improves the defects of frequent administration, gastrointestinal side effects, poor compliance and the like in traditional ketorolaco preparations.

Abstract: The application related to an ibuprofen ester derivative and an emulsion preparation thereof. A carboxyl group of racemic ibuprofen or S-ibuprofen is derivatized so that Compound N9 and a dextrorotatory enantiomer N9(S) thereof are obtained and further prepared into an emulsion preparation, which overcomes the problems of safety and compliance of patients existing in clinical application of existing ibuprofen/dexibuprofen injections and achieves the purposes of reducing vascular irritation, increasing clinical use approaches, and improving the stability of preparations in clinical applications.

Abstract: Provided is an ibuprofen ester prodrug represented by Structural Formula (1), a racemate, stereoisomer or pharmaceutically acceptable salt or solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof. Further provided are a method for preparing the compound, a pharmaceutical composition containing the compound, and an application of the compound in preparation of nonsteroidal anti-inflammatory drugs. The pharmaceutical composition containing the ibuprofen ester prodrug may be prepared into fat emulsion injection preparations. The ibuprofen ester prodrug has good stability and good pharmacokinetic properties and overcomes the problems of ibuprofen such as a short half-life, poor stability, irritation, and incompatibility.

Abstract: Provided are an arylpropionic acid derivative represented by Formula (I), a pharmaceutical composition and a preparation method and an application thereof. The arylpropionic acid derivative has a good half-life, pharmacokinetic property and in vitro stability and can enhance efficacy and reduce toxicity after formulated into preparations, which repairs the defects of frequent administration, gastrointestinal side effects and poor patient compliance of traditional nonsteroidal anti-inflammatory drugs.

Abstract: The disclosure is related to a meloxicam compositions, pharmaceutical preparations, preparation methods and use thereof. In one aspect of the invention, meloxicam compositions contain meloxicam and cosolvents. The cosolvents are mixed solvents including water and organic solvents. In another aspect of the invention, other compositions contain meloxicam, solvents, and pH regulators. The pH regulators include at least citric acid. The pharmaceutical compositions significantly enhance the solubility of meloxicam in liquid pharmaceutical preparations as well as stability. The meloxicam compositions can be directly used for intravenous injection administration to quickly reach effective therapeutic concentrations for post-operative analgesia.

Abstract: An air intake arrangement for an air intake system for an engine includes a first pre-cleaner arrangement having a housing with an air flow inlet to receive air to be pre-cleaned. A pre-cleaner region is constructed and arranged to remove at least some particulate from the inlet air. The first pre-cleaner arrangement further includes a vacuum flow path and a drop tube flow path. The vacuum flow path is in air flow communication with a first vacuum source to selectively put a vacuum draw through the pre-cleaner region. The drop tube flow path is in air flow communication with a drop tube to eject particulate removed from the inlet air by the pre-cleaner region.

Abstract: The present application discloses crystals of 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.

Abstract: The present application discloses crystals of 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.

Abstract: The invention provides a type of artemisinin derivatives having following structure I, its preparation method and use, as well as a pharmaceutical composition containing such artemisinin derivatives and its use. The arteminsinin derivatives of the present invention and their pharmaceutical composition containing the artemisinin derivatives. have immunosuppressive activities and can be used more safely. The composition which comprises the artemisinin derivatives can be formulated into long-term dosage forms such as tablet, pellet and the like, and have wider productive and use value.

Abstract: The invention provides a type of artemisinin derivatives having following structure I, its preparation method and use, as well as a pharmaceutical composition containing such artemisinin derivatives and its use. The artemisinin derivatives of the present invention and their pharmaceutical composition containing the artemisinin derivatives. have immunosuppressive activities and can be used more safely. The composition which comprises the artemisinin derivatives can be formulated into long-term dosage forms such as tablet, pellet and the like, and have wider productive and use value.